NCT00594906

Use of Teriparatide to Accelerate Fracture Healing

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effect of the drug teriparatide to the effect of placebo on pelvic fracture healing.

Detailed description

Teriparatide is a man-made form of a naturally occurring hormone called parathyroid. It increases bone density and bone strength to help prevent fractures and can be used to treat osteoporosis in people who have a high risk of bone fracture. The purpose of this study is to compare the effect of teriparatide to the effect of placebo on pelvic fracture healing. This study will last 16 weeks. Participants will be randomly assigned to receive either teriparatide or placebo for the duration of the study. Participants will also be given calcium and vitamin D supplements to take daily throughout the study. At 4-week intervals, participants will undergo functional evaluations that will include the instrumented sit-to-stand test, the timed-up-and-go, and a gait velocity test. Participants will also undergo a DXA scan upon enrollment; undergo a CT evaluation upon enrollment and 16 weeks post-fracture; and complete specific pain, self-perceived function, mental status, and depression scales throughout the study.

Conditions

• Pelvic Fracture

Interventions

Type	Name	Description
DRUG	Teriparatide	Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
DRUG	Placebo	Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2008-01-16
• Last updated: 2014-12-19
• Results posted: 2013-04-24

Locations

1 site across 1 country: United States